Form 4: Lemaitre Vascular CFO Reports Acquisition of Dividend Equivalent Rights
SEC Form 4 Filing
Joseph P. Pellegrino Jr., CFO of Lemaitre Vascular, acquired dividend equivalent rights related to previously granted restricted stock units and performance share units.
Summary
- Joseph P. Pellegrino Jr., the Chief Financial Officer of Lemaitre Vascular, has reported the acquisition of dividend equivalent rights.
- These rights are associated with previously granted restricted stock unit awards and performance share unit awards.
- The acquisitions occurred on December 5, 2024.
- The dividend equivalent rights are economically equivalent to shares of Lemaitre Vascular's common stock.
- The rights vest proportionately with the underlying awards.
Sentiment
Score: 7
Explanation: The document is a routine filing related to executive compensation. It is neither particularly positive nor negative, but indicates standard corporate governance practices.
Positives
- The acquisition of dividend equivalent rights by the CFO aligns his interests with those of shareholders.
- The vesting of these rights is tied to the performance of the underlying awards, which encourages long-term value creation.
Industry Context
This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It reflects the company's compensation practices and alignment of executive interests with shareholders.
Comparison to Industry Standards
- The use of restricted stock units and performance share units with dividend equivalent rights is a common practice in executive compensation packages for publicly traded companies, including medical device companies like Lemaitre Vascular.
- Companies such as Medtronic, Boston Scientific, and Stryker also utilize similar equity-based compensation methods to incentivize their executives.
- The vesting schedules and terms of these awards are typically designed to align with long-term company performance and shareholder value creation.
Stakeholder Impact
- The acquisition of dividend equivalent rights by the CFO aligns his interests with those of shareholders, potentially leading to better long-term performance.
- The vesting of these rights is tied to the performance of the underlying awards, which encourages long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 12/20/2019 | Date of grant for one of the restricted stock unit awards related to the dividend equivalent rights. |
| 12/02/2020 | Date of grant for one of the restricted stock unit awards related to the dividend equivalent rights. |
| 12/11/2021 | Date of grant for one of the restricted stock unit awards related to the dividend equivalent rights. |
| 12/12/2022 | Date of grant for one of the restricted stock unit awards and the performance share unit award related to the dividend equivalent rights. |
| 12/08/2023 | Date of grant for one of the restricted stock unit awards related to the dividend equivalent rights. |
| 12/05/2024 | Date of the transaction where the dividend equivalent rights were acquired. |
| 12/09/2024 | Date the form was signed. |
Keywords
dividend equivalent rights, restricted stock units, performance share units, insider trading, executive compensation, LMAT, Lemaitre Vascular, CFO, Joseph P. Pellegrino Jr.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.